Stock Events

Stock Events

Search...

State Street SPDR S&P Biotech

$127.35

306

+$2.6+2.08% Monday 21:00

Statistics

Day High

127.55

Day Low

124.03

52W High

132.09

52W Low

66.66

Volume

5,700,534

Avg. Volume

10,210,513

Mkt Cap

0

P/E Ratio

-

Dividend Yield

0.28%

Dividend

0.36

Upcoming

Dividend Payment

Dividend Payment

Dividend Payment

Dividends

0.28%Dividend Yield

Dec 25

$0.41

Sep 25

$0.03

Jun 25

$0.01

Mar 25

$0.01

Dec 24

$0

10Y Growth

8.91%

5Y Growth

55.08%

3Y Growth

179.12%

1Y Growth

-19.52%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XBI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

iShares Biotechnology

iShares Nasdaq Biotechnology ETF is a direct competitor, focusing on biotechnology and pharmaceuticals listed on the NASDAQ, similar to XBI's focus on the biotech sector.

VanEck Vectors Biotech ETF specifically targets the biotech industry, making it a close competitor to XBI with a focus on large-cap biotech companies.

First Trust NYSE Arca Biotechnology Index Fund

First Trust NYSE Arca Biotechnology Index Fund is another biotech-focused ETF, competing with XBI by investing in companies across various market caps in the biotech sector.

Invesco Biotechnology & Genome

Invesco Dynamic Biotechnology & Genome ETF competes with XBI by investing in biotech and genome companies, offering a dynamic approach to the biotech industry.

ALPS Medical Breakthroughs

ALPS Medical Breakthroughs ETF focuses on small- and mid-cap companies in the biotech and pharmaceutical sectors, competing with XBI's broader biotech focus.

Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares offers leveraged exposure to the biotechnology sector, competing with XBI by targeting similar companies but with a leveraged approach.

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares is the inverse of LABU, offering leveraged inverse exposure to the biotech sector, and competes with XBI by targeting investors looking for inverse biotech exposure.

Virtus LifeSci Biotech Products

Virtus LifeSci Biotech Products ETF competes with XBI by focusing on companies with one or more drugs in Phase II or Phase III FDA clinical trials, targeting a specific niche within the biotech sector.

Virtus LifeSci Biotech Clinical Trials

Virtus LifeSci Biotech Clinical Trials ETF is similar to BBP but focuses on companies in clinical trials, making it a competitor to XBI by targeting a specific investment strategy within the biotech industry.

About

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Show more...

CEO

Country

US

ISIN

US78464A8707

Listings

0 Comments

Share your thoughts

FAQ

What is State Street SPDR S&P Biotech stock price today?▼

The current price of XBI is $127.35 USD — it has increased by +2.08% in the past 24 hours. Watch State Street SPDR S&P Biotech stock price performance more closely on the chart.

What is State Street SPDR S&P Biotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange State Street SPDR S&P Biotech stocks are traded under the ticker XBI.

Is State Street SPDR S&P Biotech stock price growing?▼

XBI stock has fallen by -0.92% compared to the previous week, the month change is a +4.8% rise, over the last year State Street SPDR S&P Biotech has showed a +39.3% increase.

Does State Street SPDR S&P Biotech pay dividends?▼

Yes, XBI dividends are paid quarterly. The last dividend per share was 0.41 USD. As of today, Dividend Yield (FWD)% is 0.28%.

When did State Street SPDR S&P Biotech complete a stock split?▼

The last stock split for State Street SPDR S&P Biotech was on September 11, 2015 with a ratio of 3:1.